US2003161835A1PendingUtilityA1

Polypeptides from moraxella (branhamella) catarrhalis

58
Assignee: SMITHKLINE BEECHAM BIOLOGPriority: Apr 23, 1998Filed: Mar 21, 2003Published: Aug 28, 2003
Est. expiryApr 23, 2018(expired)· nominal 20-yr term from priority
Inventors:Jean-Louis Ruelle
A61K 39/00A61K 2039/51A61K 38/00C07K 14/22
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides BASB011 polypeptides and polynucleotides encoding BASB011 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . An isolated polynucleotide comprising a first polynucleotide sequence or the full complement of the first polynucleotide sequence, wherein the first polynucleotide sequence encodes a polypeptide selected from the group consisting of SEQ ID NO:2 or 4.  
     
     
         2 . The isolated polynucleotide of  claim 1 , wherein the isolated polynucleotide comprises the first polynucleotide sequence.  
     
     
         3 . The isolated polynucleotide of  claim 2 , wherein the first polynucleotide sequence encodes the polypeptide consisting of SEQ ID NO:2.  
     
     
         4 . The isolated polynucleotide of  claim 3 , wherein the isolated polynucleotide consists of the first polynucleotide sequence.  
     
     
         5 . The isolated polynucleotide of  claim 2 , wherein the first polynucleotide sequence encodes the polypeptide consisting of SEQ ID NO:4.  
     
     
         6 . The isolated polynucleotide of  claim 5 , wherein the isolated polynucleotide consists of the first polynucleotide sequence.  
     
     
         7 . An expression vector comprising the isolated polynucleotide of  claim 1 .  
     
     
         8 . A host cell comprising the expression vector of  claim 7 .  
     
     
         9 . An immunogenic composition comprising the isolated polynucleotide of  claim 1  and a pharmaceutically acceptable carrier.  
     
     
         10 . The immunogenic composition of  claim 9 , further comprising an adjuvant.  
     
     
         11 . An isolated polynucleotide comprising a first polynucleotide or the full complement of the first polynucleotide sequence, wherein the first polynucleotide sequence is selected from the group consisting of SEQ ID NO: 1, 3 or 5.  
     
     
         12 . The isolated polynucleotide of  claim 11 , wherein the isolated polynucleotide comprises the first polynucleotide sequence.  
     
     
         13 . The isolated polynucleotide of  claim 12 , wherein the first polynucleotide sequence consists of SEQ ID NO: 1.  
     
     
         14 . The isolated polynucleotide of  claim 13 , wherein the isolated polynucleotide consists of the first polynucleotide sequence.  
     
     
         15 . The isolated polynucleotide of  claim 12 , wherein the first polynucleotide sequence consists of SEQ ID NO:3.  
     
     
         16 . The isolated polynucleotide of  claim 15 , wherein the isolated polynucleotide consists of the first polynucleotide sequence.  
     
     
         17 . The isolated polynucleotide of  claim 12 , wherein the first polynucleotide sequence consists of SEQ ID NO:5.  
     
     
         18 . The isolated polynucleotide of  claim 17 , wherein the isolated polynucleotide consists of the first polynucleotide sequence.  
     
     
         19 . An expression vector comprising the isolated polynucleotide of  claim 11 .  
     
     
         20 . A host cell comprising the expression vector of  claim 19 .  
     
     
         21 . An immunogenic composition comprising the isolated polynucleotide of  claim 11  and a pharmaceutically acceptable carrier.  
     
     
         22 . The immunogenic composition of  claim 21 , further comprising an adjuvant.

Join the waitlist — get patent alerts

Track US2003161835A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.